| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | AGBL4; CCP6; Cytosolic carboxypeptidase 6; ATP/GTP-binding protein-like 4 |
| Clonality | |
| Concentration | |
| Formulation | |
| Gene ID | |
| Host | |
| Immunogen | The antiserum was produced against synthesized peptide derived from human AGBL4. AA range:431-480 |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Storage | |
| Target |
Product Overview
Primary AntibodyThis antibody targets AGBL4 and detects endogenous levels of AGBL4 protein.
Validated Applications
| Application | Dilution Guidance |
|---|---|
| Western Blot (WB) | Refer to datasheet for recommended working dilution |
| ELISA | Refer to datasheet for recommended working dilution |
Antibody Specifications
| Target | AGBL4 |
|---|---|
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Reactivity | Human |
| Purification | Affinity Purification |
| Molecular Weight | ~62.4 kDa |
| Concentration | 1 mg/ml |
| Immunogen | The antiserum was produced against synthesized peptide derived from human AGBL4. AA range:431-480 |
| Formulation | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Storage | -20°C for 1 year |
| Gene ID | Human: 84871 |
| UniProt | Q5VU57 (Human: Q5VU57; Mouse: Q09LZ8) |
Scientific Background
Metallocarboxypeptidase that mediates deglutamylation of target proteins. Catalyzes the deglutamylation of polyglutamate side chains generated by post-translational polyglutamylation in proteins such as tubulins. Also removes gene-encoded polyglutamates from the carboxy-terminus of target proteins such as MYLK. Acts as a long-chain deglutamylase and specifically shortens long polyglutamate chains, while it is not able to remove the branching point glutamate, a process catalyzed by AGBL5/CCP5.
Alternative Names
AGBL4; CCP6; Cytosolic carboxypeptidase 6; ATP/GTP-binding protein-like 4
Safety & Handling
| Target | AGBL4 |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Reactivity | Human |
| Purification | Affinity Purification |
| Molecular Weight | ~62.4 kDa |
| Concentration | 1 mg/ml |
| Immunogen | The antiserum was produced against synthesized peptide derived from human AGBL4. AA range:431-480 |
| Formulation | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Storage | -20°C for 1 year |
| Gene ID | Human: 84871 |
| UniProt | Q5VU57 (Human: Q5VU57; Mouse: Q09LZ8) |
Optimized working dilutions depend on sample type and detection system. Titration is recommended.
| Application | Dilution Note |
|---|---|
| Western Blot (WB) | Refer to datasheet for recommended working dilution |
| ELISA | Refer to datasheet for recommended working dilution |
Metallocarboxypeptidase that mediates deglutamylation of target proteins. Catalyzes the deglutamylation of polyglutamate side chains generated by post-translational polyglutamylation in proteins such as tubulins. Also removes gene-encoded polyglutamates from the carboxy-terminus of target proteins such as MYLK. Acts as a long-chain deglutamylase and specifically shortens long polyglutamate chains, while it is not able to remove the branching point glutamate, a process catalyzed by AGBL5/CCP5.
Alternative Names
AGBL4; CCP6; Cytosolic carboxypeptidase 6; ATP/GTP-binding protein-like 4
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
